Oralek s.r.o.

The department focuses on evaluating new oral anticoagulants for patients with atrial fibrillation who are at high risk of stroke or systemic embolism. The goal is to compare safety and efficacy against standard treatment.

• Comparison of novel anticoagulant with apixaban
• Assessment of major bleeding risk
• Benefit‑risk balance in stroke prevention

This work supports improved therapeutic options for individuals living with irregular heart rhythms at Oralek s.r.o..

Trials investigate the impact of reducing lipoprotein(a) on outcomes for patients with atherosclerotic cardiovascular disease. The studies aim to determine whether targeting this biomarker can lower rates of coronary heart disease death, myocardial infarction, or urgent revascularisation.

• Effect of olpasiran on cardiovascular events
• Placebo‑controlled evaluation
• Long‑term risk reduction in ASCVD

Findings could shape future preventive strategies for high‑risk heart disease patients at the clinic.

The Kardiologicka ambulancia conducts focused investigations across major cardiovascular diseases, ranging from clotting disorders to lipid abnormalities. Research seeks to bring safer, more effective treatments to the community in Namestovo, Slovakia.

• Innovative drug evaluation
• Patient‑centered outcome measures
• Collaboration with international investigators

With only two active studies, the site leverages its expertise to address critical gaps in heart health care.